Persistent atrial fibrillation
Conditions
Interventions
Experimental group:Nifekaran intravenous infusion (0.4mg/kg)
Control Group:electrical cardioversion
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years, gender is not limited; 2. Patients with persistent atrial fibrillation confirmed by electrocardiogram; 3. Those who intend to undergo catheter ablation of atrial fibrillation; 4. Those who agree to participate in this study and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who have received atrial fibrillation catheter radiofrequency ablation in the past; 2. Left atrial thrombus (confirmed by esophageal ultrasonography) or left atrial diameter >=55mm; 3. Patients with thrombocytopenia (PLT= 3 times the upper limit of normal; serum creatinine > 3.5 mg/dl); 6. Patients with abnormal thyroid function; 7. Patients with a history of surgery in the past 3 months; 8. Patients with organic diseases such as stroke, kidney damage, malignant tumor, liver and pulmonary fibrosis; 9. Life expectancy < 12 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Atrial fibrillation recurred 6 months later; | — |
Countries
China
Contacts
Public ContactXia Zirong
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed